U
ISEE

UBS’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

UBS’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$8K – 10876
2014
Q2 		$8K Buy
+200
New +$7.34K ﹤0.01% 9129

Other funds holding ISEE

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's ISEE Position: Q3 2014 in Review

UBS reduced its IVERIC bio, Inc. Common Stock (ISEE) stake by 49% in Q3 2014, selling an estimated $7.54K and leaving 199 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #9072.

UBS first reported a position in ISEE in Q4 2013 and has held it in 4 quarters since. The position peaked at $45K in Q4 2013. 92 funds tracked by Wall St. Rank hold ISEE as of Q3 2014.

  • UBS held 199 shares of IVERIC bio, Inc. Common Stock worth $8K as of Q3 2014.
  • UBS sold 192 IVERIC bio, Inc. Common Stock shares in Q3 2014, an estimated $7.54K.
  • IVERIC bio, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9072 holding.
  • UBS first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and has held it in 4 quarters since.
  • UBS's IVERIC bio, Inc. Common Stock position peaked at $45K in Q4 2013.
  • 92 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.